<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05619861</url>
  </required_header>
  <id_info>
    <org_study_id>2022/11/09</org_study_id>
    <nct_id>NCT05619861</nct_id>
  </id_info>
  <brief_title>CAR-T Cells in the Treatment of Malignant Hematological Tumors</brief_title>
  <official_title>Clinical Study of CAR-T Technique in the Treatment of Recurrent and Refractory Hematopoietic and Lymphatic Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Senlang Biotechnology Inc., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cangzhou People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hebei Senlang Biotechnology Inc., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety of autologous CAR-T cell injection in the treatment of recurrent and&#xD;
      refractory hematopoietic and lymphoid tissue tumors&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main research objective: To evaluate the safety of autologous CAR-T cell injection in the&#xD;
      treatment of recurrent and refractory hematopoietic and lymphoid tissue tumors. Secondary&#xD;
      research objective: To investigate the efficacy and cytodynamic characteristics of autologous&#xD;
      CAR-T cell injection in the treatment of recurrent and refractory hematopoietic and lymphoid&#xD;
      tissue tumors&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2020</start_date>
  <completion_date type="Anticipated">December 26, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 26, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Incidence and severity of adverse events</measure>
    <time_frame>24 months post CAR-T cells infusion</time_frame>
    <description>The incidence and severity of adverse events and adverse reactions from infusion to withdrawal or before the safety follow-up period</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Lymphoma, B-Cell</condition>
  <condition>Leukemia, B-cell</condition>
  <condition>Leukemia, T-Cell</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>CAR-T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous CAR-T cells, intravenous infusion, infusion dose 0.1-3 Ã— 106CAR-T cells/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAR-T</intervention_name>
    <description>Patients will receive CAR-T treatment</description>
    <arm_group_label>CAR-T</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. With the consent of himself or the legal guardian and the signed informed consent, he&#xD;
             is willing and able to comply with the planned visit, research and treatment,&#xD;
             laboratory examination and other test procedures; Clinical Study of CAR-T Technique in&#xD;
             the Treatment of Recurrent and Refractory Hematopoietic and Lymphatic Tumor&#xD;
&#xD;
          2. Patients with recurrent and refractory hematopoiesis and lymphoid tissue tumors&#xD;
             determined by clinical diagnosis;&#xD;
&#xD;
          3. Age 14-70 (including boundary value), both male and female;&#xD;
&#xD;
          4. Subjects with a physical status of 0~2 in the American Eastern Oncology Collaboration&#xD;
             Group (ECOG);&#xD;
&#xD;
          5. The results of treatment related antigens were positive;&#xD;
&#xD;
          6. The expected life span is more than 3 months from the date of signing the informed&#xD;
             consent;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cangzhou People's Hospital</name>
      <address>
        <city>Cangzhou</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rui Zhang</last_name>
      <phone>15350769826</phone>
      <email>dagang504@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 9, 2022</study_first_submitted>
  <study_first_submitted_qc>November 9, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2022</study_first_posted>
  <last_update_submitted>November 9, 2022</last_update_submitted>
  <last_update_submitted_qc>November 9, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Leukemia, B-Cell</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

